Archive: Company News
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
– Promising data presented at Protein and Antibody Engineering Summit (PEGS)
– Multi-functional agent targeting three immune checkpoint receptors
– Potential as mono- and combination therapy for solid tumors and blood cancers
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Company´s lead program IOS-1002. Read more…
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
– The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
– TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
– IMAG1NE utilizes biomarker-guided patient selection criteria to enroll those patients that have the highest potential for safe, deep, and durable responses
– MAGE-A1 is an attractive therapeutic target that is highly cancer specific and demonstrates significant consistency of expression between primary tumor and metastases
T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial.
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
– Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.
HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma
– Major milestone for accelerating the development of HpVac-13 in allergic diseases
HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced new data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.